(Entertainment-NewsWire.com, December 22, 2017 ) NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis. Conditions such as obesity, diabetes, hyperlipidemia, insulin resistance, and toxicity by drugs such as amiodarone, tamoxifen, and perhexiline maleate can cause NASH. Publisher's analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.
Covered in this report The report covers the present scenario and the growth prospects of the global NASH market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of off-label drugs, originally indicated for the treatment of diabetes, obesity, and associated conditions.
The market is divided into the following segments based on geography: - Americas - APAC - EMEA
Publisher's report, Global NASH Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors - Arena Pharmaceuticals - AstraZeneca - F Hoffmann-La Roche - GSK - Novo Nordisk - Vivus
